RxDoctor Payments Data

Todd Bauer, MD

Surgical Oncology · Charlottesville, VANPI 1568551034

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,329 of the $5,508 with a category attached, or 78.6%. Boehringer Ingelheim International GmbH accounts for 78.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $3,386 and has fallen 99.2% since, to $27 in 2024.

$5,508in general payments, 2019–2025

Across 18 payments — averaging $306.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$4K
  • AVEO Pharmaceuticals, Inc.$1K
  • Daiichi Sankyo Inc.$27
  • Novartis$26
$2,944in research payments, 2019–2025

Across 4 payments — averaging $736.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Novartis$219
  • Sanofi US Services Inc.$150

What the payments were for

  • Consulting fees$1,00018%
  • Speaking & faculty fees$4,32979%
  • Food & beverage$1803%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,508 in reported general payments places this provider in the 70th percentile of 28 surgical oncology providers in Virginia.

See all surgical oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$138,915
Medicare patients
146
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →